Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 459-466 , May 2008

Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study

  • Erik F.J. de Vries

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 50 3613311; fax: +31 50 3611687.
    • ,
  • Janine Doorduin

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Namkje A.R. Vellinga

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Aren van Waarde

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Rudi A. Dierckx

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Hans C. Klein

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • Department of Psychiatry, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

Received 11 December 2007 ,Accepted 11 January 2008.

References 

  1. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev. 2000;26:449–462
  2. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des. 2004;10:1493–1503
  3. Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J Clin Pharm Ther. 2003;28:203–228
  4. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–3220
  5. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer. 1996;32A:1070–1081
  6. Awara WM, El Sisi AE, El Sayad ME, Goda AE. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?. Pharmacol Res. 2004;50:487–498
  7. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol. 2003;23:665–672
  8. Ponthan F, Wickstrom M, Gleissman H, Fuskevag OM, Segerstrom L, Sveinbjornsson B, et al. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res. 2007;13:1036–1044
  9. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer. 2007;43:433–442
  10. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–684
  11. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029–1034
  12. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer. 1996;32A:1082–1088
  13. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Devane CL. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology. 2007;32:757–764
  14. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305:197–204
  15. Prabhakaran J, Majo VJ, Simpson NR, Van Heertum RL, Mann JJ, Kumar JSD. Synthesis of [C-11]celecoxib: a potential PET probe for imaging COX-2 expression. J Label Compd Radiopharm. 2005;48:887–895
  16. Prabhakaran J, Underwood MD, Parsey RV, Arango V, Majo VJ, Simpson NR, et al. Synthesis and in vivo evaluation of [18F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesul fonamide as a PET imaging probe for COX-2 expression. Bioorg Med Chem. 2007;15:1802–1807
  17. Garti N, Avrahami M, Aserin A. Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. J Colloid Interface Sci. 2006;299:352–365
  18. Hendrikse NH. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des. 2000;6:1653–1668
  19. Wegman TD, Maas B, Elsinga PH, Vaalburg W. An improved method for the preparation of [11C]verapamil. Appl Radiat Isot. 2002;57:505–507
  20. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos. 2000;28:514–521
  21. Lacroix S, Rivest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem. 1998;70:452–466
  22. Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, Sleijfer DT, et al. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer. 2004;40:2064–2070
  23. Cekic D, Bellarosa C, Garcia-Mediavilla MV, Rigato I, Pascolo L, Ostrow JD, et al. Upregulation in the expression of multidrug resistance protein Mrp1 mRNA and protein by increased bilirubin production in rat. Biochem Biophys Res Commun. 2003;311:891–896
  24. Niwa T, Yamamoto S, Saito M, Shiraga T, Takagi A. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi. 2007;127:209–216
  25. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999;47:545–552

PII: S0969-8051(08)00038-3

doi: 10.1016/j.nucmedbio.2008.01.005

Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 459-466 , May 2008

Article Tools

* Image Usage & Resolution